Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Indication
BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria
Approval of BEXSERO is based on demonstration of
Vaccination may not protect all recipients.
DON'T DISREGARD THE THREAT OF MenB
Although meningococcal disease is uncommon, it can progress quickly. In fact, it can lead to death.9
> GET THE
FACTS
EXPLORE CLINICAL DATA
BEXSERO demonstrated serum bactericidal activity against three strains selected to measure one of three vaccine antigens prevalent among strains in the U.S.1,*
*Immune response data were recorded for antigens fHbp, NadA, and PorA P1.4. However, a suitable strain for assessing immune response was not available for component NHBA.1
> SEE THE DATA
References
- Prescribing Information for BEXSERO.
- Prescribing Information for TRUMENBA.
- Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744.
- Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011;11(7):969-985.
- Ellis TN, Kuehn MJ. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev. 2010;74(1):81-94.
- Biagini M, Spinsanti M, De Angelis G, et al. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci USA. 2016;113(10):2714-2719.
- Vogel U, Taha M-K, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416-425.
- Data on file, GSK.
- Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46:S9-S15.
- MacNeil J, Cohn A. Meningococcal disease. In: Roush SW, Baldy LM, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2011. www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.pdf. Accessed February 18, 2019.
- Meningococcal vaccination: what everyone should know. Centers for Disease Control and Prevention website: https://www.cdc.gov/vaccines/vpd/mening/hcp/adolescent-vaccine.html. Last Update May 19, 2017. Accessed April 25, 2019.
- Meningococcal disease. In: Hamborsky J, Kroger A, Wolfe C, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:231-245. www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed February 18, 2019.
- Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJA. Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med. 2005;6(4):477-479.
- Vyse A, Anonychuk A, Jäkel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597-604.
- Centers for Disease Control and Prevention website. Enhanced Meningococcal Disease Surveillance Reports, 2015-2017. www.cdc.gov/meningococcal/surveillance/index.html#enhanced-reports. Updated March 28, 2017. Accessed April 1, 2019.
- MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1176.
Indication
BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.
Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.
Important Safety Information for BEXSERO
- BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
- Appropriate observation and medical treatment should always be readily available in case of an anaphylactic reaction following the administration of the vaccine
- The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
- Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
- The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
- Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
- Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
- Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with BEXSERO
- Vaccination with BEXSERO may not result in protection in all vaccine recipients
